Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1146616-03-6 | MDL No. : | MFCD18250638 |
Formula : | C5H9BN2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | SWUMSPVHWLBEHP-UHFFFAOYSA-N |
M.W : | 139.95 g/mol | Pubchem ID : | 53216598 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.4 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 38.28 |
TPSA : | 58.28 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.48 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | -0.46 |
Log Po/w (WLOGP) : | -1.59 |
Log Po/w (MLOGP) : | -1.38 |
Log Po/w (SILICOS-IT) : | -1.75 |
Consensus Log Po/w : | -1.04 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -0.72 |
Solubility : | 26.6 mg/ml ; 0.19 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.3 |
Solubility : | 70.5 mg/ml ; 0.504 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.05 |
Solubility : | 125.0 mg/ml ; 0.895 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.8 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 254 5-amino-N-(5-((2S,5R,6R)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)thiazole-4-carboxamide 254 Following the procedure for Example 101 starting from tert-butyl N-[2-bromo-4-[[5-[(2S,5R,6R)-5-(tert-butoxycarbonylamino)-6-fluoro-oxepan-2-yl]-1-methyl-pyrazol-4-yl]carbamoyl]thiazol-5-yl]carbamate (Intermediate 88), and replacing 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester with <strong>[1146616-03-6](1,3-dimethyl-1H-pyrazol-4-yl)boronic acid</strong> gave 254. 1H NMR (400 MHz, DMSO-d6) delta 9.15 (s, 1H), 7.84 (s, 1H), 7.65 (s, 1H), 7.25 (s, 2H), 5.00-4.73 (m, 2H), 4.16-3.89 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.22 (dd, J=25.0, 9.5 Hz, 1H), 2.56 (s, 3H), 2.10-2.01 (m, 1H), 1.90-1.71 (m, 3H), 1.66-1.58 (m, 1H). LCMS (ES+) m/z 449 (M+1). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 241 N-(5-((2S,5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyrazol-4-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)thiazole-4-carboxamide 241 Following the procedure for Example 101 starting from tert-butyl ((3S,4R,7S)-7-(4-(2-bromothiazole-4-carboxamido)-1-methyl-1H-pyrazol-5-yl)-3-fluorooxepan-4-yl)carbamate (Intermediate 99), and replacing 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester with <strong>[1146616-03-6](1,3-dimethyl-1H-pyrazol-4-yl)boronic acid</strong> gave 241. 1H NMR (400 MHz, DMSO-d6) delta 9.63 (s, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.84 (s, 1H), 4.95-4.83 (m, 1H), 4.83-4.62 (m, 1H), 4.42-4.28 (m, 1H), 4.24-4.05 (m, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.48 (dd, J=17.3, 8.4 Hz, 1H), 2.47 (s, 3H), 2.15-2.06 (m, 1H), 1.87 (d, J=14.4 Hz, 4H). LCMS (ES+) m/z 434 (M+1). |
[ 1071455-14-5 ]
(3-Methyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.89
[ 847818-55-7 ]
(1-Methyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.84
[ 847818-62-6 ]
(1,3,5-Trimethyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.83
[ 1138450-30-2 ]
(1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid
Similarity: 0.82
[ 1046832-21-6 ]
1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.78
[ 1071455-14-5 ]
(3-Methyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.89
[ 847818-55-7 ]
(1-Methyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.84
[ 847818-62-6 ]
(1,3,5-Trimethyl-1H-pyrazol-4-yl)boronic acid
Similarity: 0.83
[ 1138450-30-2 ]
(1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)boronic acid
Similarity: 0.82
[ 1046832-21-6 ]
1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Similarity: 0.78